COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,676 Articles (22,913 medRxiv, 8,763 bioRxiv)

Most recent first Previous |  Page 651: Articles 6501-6510  | Next

GRAd-COV2 vaccine provides potent and durable immunity in a randomised placebo-controlled phase 2 trial (COVITAR)
Capone, S., Fusco, F. M., Milleri, S., Borre', S., Carbonara, S., Lo Caputo, S., Leone, S., Gori, G., Maggi, P., Cascio, A., Lichtner, M., Cauda, R., Dal Zoppo, S., Cossu, M. V., Gori, A., Roda, S., Confalonieri, P., Bonora, S., Missale, G., Codeluppi, M., Mezzaroma, I., Capici, S., Pontali, E., Libanore, M., Diani, A., Lanini, S., Battella, S., Contino, A. M., Piano Mortari, E., Genova, F., Parente, G., Dragonetti, R., Colloca, S., Visani, L., Iannacone, C., Carsetti, R., Folgori, A., Camerini, R., the COVITAR study group
10.1101/2022.10.08.22280836 — Posted: 2022-10-10
Immune response after SARS-CoV-2 infection with residual post COVID symptoms
Pongkunakorn, T., Manosan, T., Surawit, A., Ophakas, S., Mongkolsucharitkul, P., Pumiem, S., Suta, S., Pinsawas, B., Sookrung, N., Saelim, N., Mahasongkram, K., Prangtaworn, P., Tungtrongchitr, A., Tangjittipokin, W., Boonnak, K., Narkdontri, T., Teerawattanapong, N., Jongkaewwattana, A., Mayurasakorn, K.
10.1101/2022.10.10.22280762 — Posted: 2022-10-10
Impact of the COVID-19 Vaccination Program on Case Incidence, Emergency Department Visits, and Hospital Admissions among Children Aged 5-17 Years during the Delta and Omicron Periods --United States, December 2020 to April 2022
Topf, K., Sheppard, M., Marx, G., Wiegand, R., Link-Gelles, R., Binder, A., Cool, A., Lyons, B. C., Park, S., Fast, H., Presnetsov, A., Azondekon, G. R., Soetebier, K., Adjemian, J., Barbour, K. E.
10.1101/2022.10.07.22280822 — Posted: 2022-10-10
Rehabilitation in Survivors of COVID-19 (RE2SCUE): a non-randomized, controlled and open study
Campos, M. C., Nery, T., Speck, A. E., Arpini, M., Antunes, M. M., Alves, A. C. d. B., Santos, N. d. S., Matos, M. P. P., Junior, N. S., Bicca, L. R., Panisson, C. M., Freitas, M. A., Diefenthaeler, F., Kuriki, H. U., Damin, V., da Rosa, R. O., Gress, J. B., Schneider, I. J. C., Vieira, D. S. R., Arcencio, L., Aguiar, A.
10.1101/2022.10.10.22280907 — Posted: 2022-10-10
Mitigating the Severity of COVID-19 Illness in the Primary Care Patient Population through Early Identification and Close Monitoring of Underlying Comorbidities
Parikh, P. D., Greenberg, P., Halpert, S., Abhrishami, A., Rabizadeh, L., Shayefar, H., Tetelbaun, L., Friedman, D., Kaminetzky, J.
10.1101/2022.10.07.22280827 — Posted: 2022-10-10
Associations Between Reported Post-COVID-19 Symptoms and Subjective Well-Being, Israel, July 2021 -April 2022
Gorelik, Y., Dror, A. A., Zayyad, H., Wertheim, O., Abu Jabal, K., Saleh, N., Kuodi, P., Elsinga, J., Glikman, D., Edelstein, M.
10.1101/2022.10.09.22280878 — Posted: 2022-10-10
Sensitivity of endemic behaviour of Covid-19 under a multi-dose vaccination regime, to various biological parameters and control variables
Dagpunar, J. S., Wu, C.
10.1101/2022.10.10.22280683 — Posted: 2022-10-10
Pre-pandemic humoral immunity to SARS-CoV-2 in Africa: systematic review and meta-analysis
Ioannidis, J., Contopoulos-Ioannidis, D. G.
10.1101/2022.10.07.22280814 — Posted: 2022-10-10
Cohort Profile: The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)
Staerke, N. B., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Soegaard, O. S., Tolstrup, M., Iversen, K. K., Tarp, B., Larsen, F. D., Larsen, L., Lindvig, S. O., Holden, I. K., Iversen, M. B., Knudsen, L. S., Fogh, K., Jakobsen, M. L., Traytel, A., Oestergaard, L., Lundgren, J.
10.1101/2022.10.09.22280886 — Posted: 2022-10-10
Comparison of COVID-19 Antigen Rapid Test (Oral Fluid) and Real-Time RT-PCR in the laboratory diagnosis of SARS-CoV-2 infection
Mense, L. M., Ouburg, S.
10.1101/2022.10.07.22280607 — Posted: 2022-10-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).